September 2014. Volume 10. Number 3

Motavizumab is not efficacious as a treatment of respiratory syncytial virus bronchiolitis

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Ramilo O, Lagos R, Sáez-Llorens X, Suzich J, Wang CK, Jensen KM, et al; Motavizumab Study Group. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J. 2014;33:703-9.
Reviewers: Ochoa Sangrador C1, González de Dios J2.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 14/08/2014
Acceptance date: 25/08/2014
Publication date: 03/09/2014

Abstract

Authors' conclusions: motavizumab has no effect on viral load, nor improves the clinical course of patients admitted with lower respiratory tract infection caused by respiratory syncytial virus.

Reviewers' commentary: motavizumab does not improve the clinical course of infants with lower respiratory tract infection caused by respiratory syncytial virus. Interestingly, the treated cases have a tendency to have worse clinical outcomes, which is significant for the risk of admission to intensive care and mechanical ventilation.

How to cite this article

Ochoa Sangrador C, González de Dios J. El motavizumab no es eficaz como tratamiento de las bronquiolitis por virus respiratorio sincitial. Evid Pediatr. 2014;10:48.

AVC | Critically appraised articles

Ramilo O, Lagos R, Sáez-Llorens X, Suzich J, Wang CK, Jensen KM, et al; Motavizumab Study Group. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J. 2014;33:703-9.
Reviewers: Ochoa Sangrador C1, González de Dios J2.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 14/08/2014
Acceptance date: 25/08/2014
Publication date: 03/09/2014

How to cite this article

Ochoa Sangrador C, González de Dios J. El motavizumab no es eficaz como tratamiento de las bronquiolitis por virus respiratorio sincitial. Evid Pediatr. 2014;10:48.

References

  1. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531-7.
  2. González de Dios J, Balaguer Santamaría A. Nuevas sombras en los estudios de coste-efectividad del palivizumab frente al virus respiratorio sincitial. Evid Pediatr. 2013;9:13.
03/09/2014

Linked Comment